Isotope enhanced ambroxol for long lasting autophagy induction

Patent metadata

Field	Value
Publication number	US-10583099-B2
Application number	US-201916412017-A
Country	US
Kind code	B2
Filing date	May 14, 2019
Priority date	Feb 7, 2017
Publication date	Mar 10, 2020
Grant date	Mar 10, 2020

Abstract

The present invention is directed to 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy) are also disclosed. These compositions are useful against an autophagy mediated disease state and/or condition), especially an autophagy mediated disease state and/or condition which occurs in the lungs.

First claim

We claim:

1. A compound according to the chemical structure:

a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.

2. The compound according to claim 1 which is

a pharmaceutically acceptable salt or enantiomer thereof.

3. The compound according to claim 1 which is

a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising an effective amount to modulate autophagy in a patient or subject of at least one compound according to claim 1 , in combination with a pharmaceutically acceptable carrier, additive or excipient.

5. The composition according to claim 4 further including at least one additional bioactive agent selected from the group consisting of an additional autophagy modulator, an anti-tuberculosis agent and an anti-cancer agent.

6. The composition according to claim 5 wherein said bioactive agent is an additional autophagy modulator.

7. The composition according to claim 5 wherein said additional bioactive agent is an anti-tuberculosis agent.

8. The composition according to claim 7 wherein said anti-tuberculosis agent is a rifamycin.

9. The composition according to claim 8 wherein said rifamycin is rifampin, rifabutin, rifamixin, rifapentine or a mixture thereof.

10. The composition according to claim 8 wherein said rifamycin is rifampin, rifabutin or a mixture thereof.

11. The composition according to claim 8 wherein said rifamycin is rifampin.

12. The composition according to claim 5 wherein said anti-tuberculosis agent is ethambutol, isoniazid, ethionamide, propionamide, pyrazinamide, rifampin or a mixture thereof.

13. The composition according to claim 5 wherein said additional autophagy modulator is astemizole, chrysophanol, emetine, chlorosalicylanilide, oxiconazole, sibutramine, proadifen, dihydroergotamine tartrate, terfenadine, triflupromazine, amiodarone, saponin, vinblastine, tannic acid, fenticlor, pizotyline malate, piperacetazine, oxyphencyclimine, glyburide, hydroxychloroquine, methotrimeprazine, mepartricin, thiamylal sodium, triclocarban, diphenidol, karanjin, clovanediol diacetate, nerolidol, fluoxetine, helenine, dehydroabietamide, dibutyl phthalate, 18-aminoabieta-8,11,13-triene sulfate, podophyllin acetate, berbamine, rotenone, rubescensin A, morin, pyrromycin, Pomiferin, Gardenin A, alpha-mangostin, Avocadene, Butylated hydroxytoluene, Physcion, Tetrandrine, Malathion, Isoliquiritigenin, Clofoctol, Isoreserpine, 4, 4′-dimethoxydalbergione and 4-methyldaphnetin and mixtures thereof.

14. The composition according to claim 5 wherein said additional bioactive agent is an anticancer agent.

15. The composition according to claim 14 wherein said anticancer agent is effective for treating lung cancer and is selected from the group consisting of cisplatin, carboplatin, paclitaxel, albumin-bound paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine, pemetrexed and mixtures thereof.

16. The composition according to claim 5 wherein said additional bioactive agent is at least one additional autophagy modulator, anti-tuberculosis agent or a mixture thereof.

17. The composition according to claim 16 in inhalation or pulmonary dosage form.

18. The composition according to claim 17 wherein said compound and additional bioactive agent are included in said composition as particles having a mean diameter within the range of 0.05 to 20 microns.

19. The composition according to claim 17 wherein said compound and additional bioactive agent are included in said composition as particles having a mean diameter within the range of about 0.05 to about 0.25 microns.

20. The composition according to claim 17 wherein said compound and additional bioactive agent are included in said composition as particles having a mean diameter within the range of about 1 to about 3 microns.

21. The composition according to claim 5 in dry powder inhalation dosage form.

22. The composition according to claim 5 in metered inhalation dosage form.

23. The composition according to claim 4 further including at least one compound selected from the group consisting of benzethonium, niclosamide, monensin, bromperidol, levobunolol, dehydroisoandosterone 3-acetate, sertraline, tamoxifen, reserpine, hexachlorophene, dipyridamole, harmaline, prazosin, lidoflazine, thiethylperazine, dextromethorphan, desipramine, mebendazole, canrenone, chlorprothixene, maprotiline, homochlorcyclizine, loperamide, nicardipine, dexfenfluramine, nilvadipine, dosulepin, biperiden, denatonium, etomidate, toremifene, tomoxetine, clorgyline, zotepine, beta-escin, tridihexethyl, ceftazidime, methoxy-6-harmalan, melengestrol, albendazole, rimantadine, chlorpromazine, pergolide, cloperastine, prednicarbate, haloperidol, clotrimazole, nitrofural, iopanoic acid, naftopidil, methimazole, trimeprazine, ethoxyquin, clocortolone, doxycycline, pirlindole mesylate, doxazosin, deptropine, nocodazole, scopolamine, oxybenzone, halcinonide, oxybutynin, miconazole, clomipramine, cyproheptadine, doxepin, dyclonine, salbutamol, flavoxate, amoxapine, fenofibrate and pimethixene or a pharmaceutically acceptable salt thereof.

24. The composition according to claim 4 in oral, inhalation or pulmonary dosage form.

25. The composition according to claim 4 in inhalation or pulmonary dosage form.

26. The composition according to claim 25 wherein said compound is included in said composition as particles having a mean diameter within the range of 0.05 microns to 5 microns.

27. The composition according to claim 4 in nebulizer suspension dosage form.

Assignees

• Stc Unm

Inventors

• Timmins Graham
• Deretic Vojo P

Classifications

• C07B59/001

  Acyclic or carbocyclic compounds · CPC title

• A61P31/06

  for tuberculosis · CPC title

• A61K45/00

  Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title

• A61K35/00

  Medicinal preparations containing materials or reaction products thereof with undetermined constitution · CPC title

• A61P11/00 Primary

  Drugs for disorders of the respiratory system · CPC title